Skip to main content
. Author manuscript; available in PMC: 2013 Jan 22.
Published in final edited form as: N Engl J Med. 2008 Jul 2;359(4):366–377. doi: 10.1056/NEJMoa0800668

Figure 1. Correlation between the Presence of T790M Mutations in Tumor-Biopsy Specimens and Decreased Progression-free Survival.

Figure 1

In patients with non–small-cell lung cancer with EGFR mutations who were receiving therapy with gefitinib or erlotinib, the presence of the drug-resistance mutation T790M before initiation of treatment was associated with decreased progression-free survival.